{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'When olaparib is combined with the mono-methylating agent TMZ, potentiation of its anti-', 'tumor activity across a number of cancer cell lines is observed. Moreover, other PARP', 'inhibitors have also been shown to be effective with a number of non-classical alkylating', 'agents including MMS, DTIC and TMZ. However, for the \"classic\" alkylating agents such as', \"cyclophosphamide and N, N'-bis(2-chloroethyl)-N-nitrosourea (BCNU; carmustine) only\", 'some early literature reports are available on showing potentiation but, to date, no data have', 'been generated for olaparib with such agents. Similarly, the effectiveness of olaparib with', 'topoisomerase I inhibitors (i.e., camptothecin family) and platinum agents (e.g., cisplatin and', 'carboplatin) has been shown in both in vitro and in vivo studies.', '1.3.2', 'Toxicology and safety pharmacology summary', 'The toxicology and safety pharmacology is fully described in the current version of the', \"olaparib Investigator's Brochure (IB).\", 'In repeat dose oral toxicity studies of up to 6 months duration in rats and dogs, the principal', 'target organ for toxicity was the bone marrow, with associated changes in peripheral', 'hematology parameters, which may be related to the primary pharmacology of olaparib. All', 'changes showed full or partial recovery following withdrawal of olaparib.', 'Olaparib was not mutagenic in an Ames bacterial mutation test, but was clastogenic in a CHO', 'chromosome aberration test in vitro. When dosed orally, olaparib also induced micronuclei in', 'bone marrow of rats. These findings are consistent with genomic instability resulting from the', 'primary pharmacology of olaparib.', 'In reproductive toxicology studies in rats, oral dosing of olaparib prior to mating produced no', 'adverse effects on male fertility. In female rats, although conception rates were unaffected by', 'pre- and peri-conception dosing, embryofetal survival was decreased. Administration of', 'olaparib during organogenesis had an adverse effect on embryofetal survival and also', 'increased major fetal malformations at dose levels that were not maternally toxic. The effects', 'on embryofetal development are considered to be related to the primary pharmacology of', 'olaparib.', 'Exposures in the repeat dose and reproductive toxicology studies were below those achieved', 'at the clinical therapeutic doses of 400 mg bd olaparib (capsule) and 300 mg bd (tablet).', 'Combination studies in rats suggest potential for olaparib to exacerbate the effects of TMZ', 'and topotecan, although combination of olaparib with these anti-cancer agents did not induce', 'any additional target organ toxicities to those seen with single agent administration.', 'Monotherapy', 'Data from the development program indicate that olaparib is generally well tolerated at', 'monotherapy doses up to 400 mg bd (capsule formulation) and 300 mg bd (tablet formulation)', 'in patients with solid tumors. Administration of olaparib monotherapy has been associated', 'with adverse reactions generally of mild or moderate severity (CTCAE Grade 1 or 2) and', 'generally not requiring treatment discontinuation.', '20(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Combination studies', 'Studies of olaparib in combination with various chemotherapy agents indicate an increase in', 'bone marrow toxicity (anemia, neutropenia, thrombocytopenia) greater than expected if the', 'agents had been administered alone. The effects are generally transient but treatment delays', 'are common and alternative administration schedules/toxicity management processes have', 'been evaluated within some of these studies. When this type of toxicity has occurred it has', 'been managed by routine clinical practice including dose delays, dose reductions, intermittent', 'dosing and/or the use of supportive care measures, including G-CSF.', '1.3.3', 'Clinical experience', 'Clinical experience with olaparib is fully described in the current version of the olaparib', \"Investigator's Brochure.\", '1.3.3.1', 'Olaparib in mCRPC', 'Failure to accurately repair DNA damage can lead to the accumulation of mutations, and an', 'increased cancer risk [83, 84]. Not surprisingly, mutations in DNA repair genes have been', 'associated with several cancer predisposition syndromes [85-87]. It has also been shown', 'across a variety of malignancies that when DNA damage repair deficiency occurs - often as a', 'result of homozygous loss of function mutations in BRCA 1/2, ATM and other genes involved', 'in homologous recombination - alternative DNA repair mechanisms are required to prevent', 'genomic instability and cell death. Poly (ADP-ribose) polymerase (PARP) has been shown to', 'be a key mediator in this respect. As such, strategies to inhibit PARP activity have been', 'shown to be effective in a number of cancers with impaired homologous recombination [70,', '88-91]. In addition, more recent data has shown that PARP inhibition may be an effective', 'strategy to augment the antitumor effects of other DNA damaging agents (e.g. alkylating and', 'platinum chemotherapies) in cancers with intact DDR pathways [91, 92].', 'As part of our participation in the SU2C/AACR/PCF Prostate Cancer Dream Team, we have', 'found that ~20% of CRPC patients harbor biallelic loss of a DNA damage repair (DDR)', 'pathway gene [35]. In addition, more recent studies from our group have demonstrated that in', 'men with metastatic prostate cancer, there is a high incidence (~12%) of deleterious alteration', 'in DDR genes [87]. This data provides a strong rationale for a precision oncology approach to', 'treating advanced prostate cancer with drugs that impair DDR (e.g. PARP inhibitors). Proof of', 'concept for this approach is derived from the TOPARP Trial [88]. This was a Phase II study', 'testing olaparib 400 mg by mouth twice daily in men with metastatic CRPC. The primary', 'endpoint was response rate, which was defined as either an objective radiographic response', 'per RECIST criteria v1.1, a PSA reduction of >50% from baseline (i.e., PSA50 response) or a', 'confirmed reduction in circulating tumor cells (CTCs) from >5 cells per 7.5 mL of blood to <5', 'cells per 7.5 mL of blood. Fifty patients were enrolled, and all were post-docetaxel. Forty-nine', 'patients received prior abiraterone or enzalutamide. Sixteen patients (33%) met the primary', 'endpoint. Responses to olaparib were enriched in the subset of patients with homozygous', \"deletions, deleterious mutations, or both in DDR genes (e.g. BRCA1/2, ATM, Fanconi's\", 'anemia genes, and CHEK2) (Figure 10). In this cohort, response rate was 88%. The observed', 'safety profile of olaparib was consistent with that observed in other solid tumor trials. On the', '21(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}